ID   A2780-DX2
AC   CVCL_4T96
DR   cancercelllines; CVCL_4T96
DR   Wikidata; Q54606567
RX   PubMed=2598402;
CC   Population: African American.
CC   Selected for resistance to: ChEBI; CHEBI:28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Sequence variation: Mutation; HGNC; 795; ATM; Simple; p.Pro604Ser (c.1810C>T); ClinVar=VCV000127343; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys128_Arg130del (c.383_391del9); Zygosity=Unspecified (from parent cell line).
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C7979; Ovarian endometrioid adenocarcinoma
DI   ORDO; Orphanet_454723; Endometrioid carcinoma of ovary
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_4T95 ! A2780-DX1
SX   Female
AG   Age unspecified
CA   Cancer cell line
DT   Created: 22-09-15; Last updated: 05-10-23; Version: 11
//
RX   PubMed=2598402; DOI=10.1007/BF00692343;
RA   Alaoui-Jamali M.A., Yin M.-B., Mazzoni A., Bankusli I., Rustum Y.M.;
RT   "Relationship between cytotoxicity, drug accumulation, DNA damage and
RT   repair of human ovarian cancer cells treated with doxorubicin:
RT   modulation by the tiapamil analog RO11-2933.";
RL   Cancer Chemother. Pharmacol. 25:77-83(1989).
//